Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
Authors:
Open Access
- 15 November 2022
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 66 (11) , e0095122
Abstract
LHF-535 is a small-molecule antiviral currently under development as a therapeutic option to treat Lassa fever and other viral hemorrhagic fevers of arenavirus origin. The human safety and pharmacokinetics of LHF-535 were evaluated in two phase 1 trials in healthy volunteers.Keywords
Funding Information
- Wellcome Trust (WT-200439/Z/16/Z)
This publication has 10 references indexed in Scilit:
- Time to reconsider the role of ribavirin in Lassa feverPLOS Neglected Tropical Diseases, 2021
- Ranking the risk of animal-to-human spillover for newly discovered virusesProceedings of the National Academy of Sciences, 2021
- Lassa fever outcomes and prognostic factors in Nigeria (LASCOPE): a prospective cohort studyThe Lancet Global Health, 2021
- Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysisInternational Journal of Infectious Diseases, 2019
- Caseload and Case Fatality of Lassa Fever in Nigeria, 2001–2018: A Specialist Center's Experience and Its ImplicationsFrontiers in Public Health, 2019
- A potent Lassa virus antiviral targets an arenavirus virulence determinantPLOS Pathogens, 2018
- A simple practice guide for dose conversion between animals and humanJournal of Basic and Clinical Pharmacy, 2016
- A Prospective Study of the Epidemiology and Ecology of Lassa FeverThe Journal of Infectious Diseases, 1987
- Epidemiology and Control of Lassa Fever1987
- Lassa FeverNew England Journal of Medicine, 1986